Recent Updates
Recently added Catalysts

VR 9250 / DR 9550 / CRT 9750

Phase 3

Heart Failure | Unknown | Cardiovascular |LivaNova PLC|Last Updated: Jun 18, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment75
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01193634Clinical Evaluation Of The PARADYM RF DevicePHASE3 COMPLETED 75Oct 1, 2010Mar 1, 2012Jun 18, 20141 Germany
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Demonstration of the Right ventricular (RV) autothreshold algorithm performances
1 month

Demonstrate that the automatic RV pacing thresholds measures are equivalent to the manual test.

Secondary Endpoints
Incidence of adverse events
12 months
ICD electrical performances
12 months
Evaluation of the left ventricular lead performances
12 months
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeDIAGNOSTIC
Treatment Arms
ArmTypeDescription
Paradym RF ICDEXPERIMENTALActive implantable defibrillators range
Interventions
NameTypeDescription
VR 9250 / DR 9550 / CRT 9750DEVICEActive implantable defibrillators range
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * In case of implantation of VR 9250: patient has been prescribed the implantation or replacement of a single-chamber ICD system accordingly to the relevant currently-approved ACC/AHA/ESC2 guidelines or any relevant currently-approved local guidelines for the implantation or rep...

Countries:Germany
Unlock Eligibility Criteria